Previous 10 | Next 10 |
home / stock / esalf / esalf news
Derived From Total Synthesis of Halichondrin Found in Joint Research Between Eisai and Harvard University Scientists, Published in Scientific Reports TOKYO, June 18, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that a joint research group including scientists from Eisai and Profes...
TOKYO, June 18, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 33rd International Epilepsy Congress (IEC) to be held from June 22 to 26, 2019 in Bangkok, Thailand. As maj...
TOKYO, May 17, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai has received approval from "Science Based Targets (SBT) Initiative" for Eisai's mid and long-term targets for greenhouse gas (GHG) reduction. "SBT Initiative" is an international joint initiative by CDP which i...
TOKYO, May 16, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates regarding its in-house discovered lenvatinib mesylate (product name: Lenvima, "lenvatinib", kinase inhibitor), eribulin mesylate (product name: Halaven, "erib...
Eisai Co Ltd (ESALF) Q4 2019 Earnings Conference Call May 13, 2019, 03:00 ET Company Participants Haruo Naito - CEO Masanori Tsuno - Deputy Chief Clinical Officer, Neurology Business Group Ryohei Yanagi - SVP, CFO & Chief IR Officer Yasushi Okada - Chief Talent Officer, Ind...
The following slide deck was published by Eisai Co., Ltd. in conjunction with their 2018 Q4 earnings Read more ...
Eisai ( OTCPK:ESALF ): FY GAAP EPS of ¥221.12. More news on: Eisai Co., Ltd., Eisai Co., Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...
TOKYO, May 10, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a license agreement with medac Gesellschaft fur klinische Spezialpraparate mbH for the commercialization of its anti-rheumatic agent methotrexate (MTX) subcutaneous injection (pre-filled syringe) in...
For Upcoming Clinical Studies on Prevention of Alzheimer's Disease TOKYO, May 10, 2019 - (JCN Newswire) - The Alzheimer's Clinical Trials Consortium (ACTC) and Eisai Co., Ltd. announced today that the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (developme...
TOKYO, May 9, 2019 - (JCN Newswire) - Eisai Co., Ltd. and Allm Inc. have entered into a capital and business alliance agreement for ICT digital health solutions in various areas as well as regional medical treatment and care. Under this capital and business alliance, the two companies will col...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel TOKYO and CAMBRIDGE, Mass., July 12, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMB...
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong TOKYO and CAMBRIDGE, Mass., July 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated ...
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) TOKYO, July 2, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squi...